Rhonda Farnum - 10 Feb 2025 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
SVP, COMM & MEDICAL AFFAIRS
Signature
/s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
10 Feb 2025
Net transactions value
-$152,725
Form type
4
Filing time
24 Feb 2025, 19:24:52 UTC
Previous filing
23 Jan 2025
Next filing
04 Mar 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +5,283 +1.7% $0.000000 314,848 10 Feb 2025 Direct F1
transaction TBPH Ordinary Shares Tax liability $152,725 -15,810 -5% $9.66 299,038 20 Feb 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On April 2, 2024 the reporting person was granted a performance restricted stock unit award that vests based on the achievement of certain performance conditions and continued employment. On February 10, 2025, the performance conditions were deemed achieved as to 5,283 RSUs, and such RSUs became eligible to vest based on the reporting person's continued service.
F2 Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.